Ascelia Pharma
Ascelia Pharma AB is a Swedish biopharmaceutical company developing orphan oncology drugs for specialized cancer treatments. The company focuses on developing diagnostic and therapeutic products, including its lead candidate Orviglance, an oral contrast agent for liver MRI scans in patients with kidney impairment. Revenue is primarily generated through research funding, licensing partnerships, and capital raises ahead of commercial market authorization. Core end markets serve hospital radiology departments, oncology clinics, and specialized renal care units globally. Ascelia Pharma occupies a distinct position in the European orphan drug sector through its targeted diagnostic imaging solutions. The company is headquartered in Malmö, Sweden, and its shares trade on the Nasdaq Stockholm exchange.
3 of the funds FundTelligence covers report a position in Ascelia Pharma.
- Legal name
- Ascelia Pharma AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 3
Funds holding Ascelia Pharma
- Handelsbanken Norden Index Criteria — Handelsbanken · 0.0 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Småbolag Plus — Storebrand · 0.0 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.0 % (full portfolio disclosed, October 2026)